

## Press release

Lund July 23rd, 2019

EQL Pharma AB (publ)

Org.no. 556713-3425



## Change in holdings for Fårö Capital in EQL Pharma AB

Fårö Capital AB, Christer Fåhraeus investment company, has today press released a change of its shareholding in EQL Pharma AB, see attached press release from Fårö Capital AB (only in Swedish).

For further information, please contact:

Christer Fåhraeus

CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

Email: [christer.fahraeus@eqlpharma.com](mailto:christer.fahraeus@eqlpharma.com)

Website: [www.eqlpharma.com](http://www.eqlpharma.com)

### About EQL Pharma

EQL Pharma AB is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently has 16 niche generics (i.e. generics with little or no competition except for the original medicine) approved on the Swedish and Danish markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2019 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma AB is based in Lund, Sweden, employs 8 people and is listed on Spotlight Stock Market. EQL Pharma AB also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.